Organovo Holdings,
Organovo develops 3D printed human tissues to revolutionize drug discovery and medical research.
- CEO / Founder
- Keith Murphy
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- $100M
- Latest Round
- Acquired
- Key Investors
- Methuselah Foundation, Lifeline Ventures
Technology & Products
Key Products
["ExVive3D liver tissue","3D printed kidney tissue"]
Technological Advantage
Advanced 3D bioprinting technology enabling the creation of complex tissue structures that improve drug efficacy testing.
Differentiation
Value Proposition
Provides innovative 3D bioprinted tissues that offer more accurate drug testing and potential for organ transplantation.
How They Differentiate
Focuses on developing functional tissues tailored for drug testing and potential organ transplantation, unlike competitors who primarily emphasize bioprinting technology.
Market & Competition
Target Customers
Pharmaceutical companies and medical research institutions
Industry Verticals
["Biotechnology","Pharmaceutical","Medical Research"]
Competitors
CELLINK; Aspect Biosystems; BioLife Solutions
Growth & Milestones
Growth Metrics
Significant stock price increase following the Eli Lilly deal
Major Milestones
["Successfully developed and tested 3D printed kidney tissue","Partnered with the University of Virginia","Sold the FXR program to Eli Lilly"]
Notable Customers
Eli Lilly